



NSC RESEARCH CURRENTLY ENROLLING TRIALS

5400 Laurel Springs Parkway Suite 1402 Johns Creek, GA 30024

1100 Northside Forsyth Dr Suite 345 Cumming GA 30041

Phone 678-507-0838 Fax 470-695-7565

Director - Narendra Singh, MD, FRCPC, FCCS, FACC, FAHA

Research Administrator- Crystal Richards

Research Coordinators: Julianna Zabala CCMA CCRC, Charlotte Mall, BS CCRC, Katherine Byrne MA CRC

HEART FAILURE

- ☐ **EASi-HF PRESERVED**→ Vicadrostal and empagliflozin compared with placebo and empagliflozin tablets in participants with heart failure and preserved ejection fraction (EF >40%) – *testing an oral aldosterone synthetase inhibitor to reduce death and hospitalization for heart failure*
- ☐ **EASi-HF REDUCED**→ Vicadrostal and empagliflozin compared with placebo and empagliflozin tablets in participants with heart failure and reduced ejection fraction (EF >40%) – *testing an aldosterone synthetase inhibitor to reduce death and hospitalization for heart failure*
- ☐ **HF-POLARIS**→ Amycretin compared to placebo injections in patients with heart failure and preserved ejection fraction (EF>40%) as well as being overweight BMI > 27 or obese BMI > 30 – *testing if a weight loss drug with GLP-1 like properties can improve quality of life, exercise tolerance and reduce hospitalization rates for heart failure*

ATRIAL FIBRILLATION

- ☐ **LILAC** → Abelaclimab vs placebo injections in patients with atrial fibrillation normally unsuitable for anticoagulation therapy – *testing if a factor XI inhibitor can reduce the risk of strokes while minimizing bleeding risk*
- ☐ **ROXI-ATLAS**→ Regn7508 and Regn9933 vs apixaban in patients with Atrial Fibrillation – *testing the bleeding safety profile of these two Factor XI inhibitors injections compared to oral apixaban*
- ☐ **ROXI-EVERST**→ REGN7508 vs apixaban in patients with Atrial Fibrillation - *testing this Factor XI inhibitor injection compared to oral apixaban to reduce the risk of stroke or systemic embolization*

OVERWEIGHT and OBESITY

- ☐ **MARITIME-SWITCH**→ Switching from a GLP-1 RA semaglutide or tirzepatide to Maridebart Cafraglutide in NON-diabetic adult participants with obesity BMI>30 or overweight BMI>27 who have stabilized their weight loss on full dose – *testing if the switch to the new injectable agent can cause additional weight loss*



NSC RESEARCH CURRENTLY ENROLLING TRIALS

5400 Laurel Springs Parkway Suite 1402 Johns Creek, GA 30024

1100 Northside Forsyth Dr Suite 345 Cumming GA 30041

Phone 678-507-0838 Fax 470-695-7565

Director - Narendra Singh, MD, FRCPC, FCCS, FACC, FAHA

Research Administrator- Crystal Richards

Research Coordinators: Julianna Zabala CCMA CCRC, Charlotte Mall, BS CCRC, Katherine Byrne MA CRC

DIABETES/CARDIOVASCULAR/HYPERTENSION

- ☐ **PREVENT-HF → Baxdrostat in combination with dapagliflozin compared with dapagliflozin alone in Type 2 diabetic hypertensive cardiac patients– *testing this oral aldosterone synthetase inhibitor's ability to reduce the risk of Incident Heart Failure and Cardiovascular Death***
- ☐ **EASI-PROTKT → Vicadrostat in combination with empagliflozin compared with empagliflozin alone in Type 2 diabetic hypertensive cardiac patients– *testing this oral aldosterone synthetase inhibitor ability to reduce the risk of Incident Heart Failure and Cardiovascular Death***

LIPO(A)/CARDIOVASCULAR

- ☐ **OCEAN (a) PREVENT → Olpasiran compared to placebo in high-risk cardiac patient with elevated LP(a) – *Testing if this monoclonal antibody monthly injection can reduce the risk of major cardiovascular events by lowering LP(a) levels***


HYPERTENSION

- ☐ **ZENITH → Zilebesiran compared to Placebo plus Standard of Care in patients with Hypertension Not Adequately Controlled and Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease - *Testing if this siRNA twice yearly injection can reduce the risk of major cardiovascular events***

IF YOU OR SOMEONE YOU KNOW MAY BE INTERESTED- PLEASE CONTACT OUR RESEARCH TEAM TO SEE IF YOU QUALIFY FOR PARTICIPATION IN ONE OF THESE TRIALS – NSC RESEARCH INC IS AN AWARD WINNING, INTERNATIONALLY RECOGNIZED, HIGHLY EXPERIENCED, RESEARCH UNIT



k34452923 fotosearch.com ©



k0089831 www.fotosearch.com ©